YOL118C Antibody

What is YOL118C and what cellular functions might antibodies against it help study?

YOL118C has been identified in genomic studies related to oxidative stress tolerance mechanisms . While specific antibodies against YOL118C are not directly described in the available literature, this gene appears alongside other stress-responsive genes including ADH1, MSH2, CRT10, and MPD2 . Antibodies targeting YOL118C would likely be valuable for studying:

• Protein expression patterns during oxidative stress responses

• Protein-protein interactions in stress tolerance pathways

• Post-translational modifications that may regulate its activity

Methodologically, researchers would need to establish specificity of any YOL118C antibody through validation techniques such as western blotting against knockout/knockdown samples or immunoprecipitation followed by mass spectrometry.

How can researchers validate YOL118C antibody specificity?

Antibody validation is critical for ensuring experimental reliability. For YOL118C antibodies, researchers should implement multiple validation approaches:

• Western blot analysis comparing wild-type samples against YOL118C knockout/knockdown samples

• Competition assays using purified recombinant YOL118C protein

• Cross-reactivity testing against related proteins

• Immunoprecipitation followed by mass spectrometry

Drawing from established antibody validation protocols, researchers can adapt the methodologies used for CD26 antibody validation, where multiple antibody clones (e.g., 5K78 and M-A261) were tested to ensure specificity, and competition/cross-blocking experiments were performed to validate binding characteristics .

What expression systems are recommended for producing YOL118C antibodies?

Based on established antibody production practices:

• Hybridoma technology: Suitable for mouse monoclonal antibody production

• Phage display: Effective for generating recombinant antibody fragments

• HEK293 or CHO cell expression: Recommended for full-length humanized or chimeric antibodies

Following production, purification should include affinity chromatography (typically Protein A/G for IgG antibodies) followed by size-exclusion chromatography. Quality control should assess:

• Purity (≥95% by SDS-PAGE)

• Endotoxin levels (<1 EU/mg)

• Aggregation (<5% by size-exclusion chromatography)

• Binding affinity (determined by ELISA or surface plasmon resonance)

How can researchers optimize immunophenotyping protocols using YOL118C antibodies?

For effective immunophenotyping with YOL118C antibodies, researchers should adapt protocols similar to those used for CD26 immunophenotyping:

• Clone selection: Test multiple antibody clones to identify those that maintain specificity under experimental conditions

• Competition assays: Perform validation using increasing dilutions of blocking peptide

• Cross-blocking experiments: Assess epitope accessibility in different sample preparations

In CD26 research, investigators discovered that clone M-A261 showed a dramatic decrease in CD26+ cells after therapeutic antibody administration due to epitope masking, while clone 5K78 maintained consistent detection . This highlights the importance of clone selection and validation. Researchers should establish baseline detection parameters and monitor any variations in YOL118C expression across different cellular subpopulations.

What pharmacodynamic monitoring approaches should be implemented when using YOL118C antibodies in vivo?

Based on established practices in antibody pharmacodynamics monitoring, researchers should:

• Establish baseline measurements: Determine normal expression levels of YOL118C in relevant tissues

• Develop sensitive detection assays: Create ELISA or other quantitative assays for:

  • Free antibody levels

  • Target engagement (bound vs. unbound antibody)

  • Total and free target antigen levels

• Monitor temporal dynamics: Sample at multiple timepoints following administration:

  • Early (1-48 hours): Assess initial target engagement and distribution

  • Intermediate (1-2 weeks): Evaluate sustained effects

  • Extended (>1 month): Determine long-term biological impacts

Drawing from YS110 antibody studies, researchers should consider monitoring changes in:

• Target protein levels in circulation

• Enzyme activity (if YOL118C has enzymatic functions)

• Changes in related biomarkers

• Potential immunological responses to the antibody

How can engineered YOL118C antibodies with enhanced antigen-sweeping capabilities be developed?

To create YOL118C antibodies with enhanced antigen-clearing properties, researchers can apply engineering strategies like those used in developing "sweeping antibodies":

• pH-dependent binding engineering: Modify the antigen-binding region to bind strongly at neutral pH (pH 7.4) but dissociate at acidic endosomal pH (pH 5.5-6.0)

• FcRn binding enhancement: Engineer the Fc region to increase binding to neonatal Fc receptor at neutral pH

These modifications enable a novel mechanism where:

• Antibody binds to antigen in circulation

• The antibody-antigen complex is internalized via FcRn-mediated endocytosis

• Antigen dissociates from antibody in acidic endosomes

• Antibody recycles to the cell surface via FcRn while antigen is degraded

This approach has demonstrated 50-1000 fold reductions in antigen levels compared to conventional antibodies . Such engineering would be particularly valuable if YOL118C or its product functions as a soluble factor that requires clearance from circulation.

What imaging protocols are recommended for YOL118C cellular localization studies?

For effective subcellular localization of YOL118C using antibodies:

• Sample preparation:

  • Fixation: 4% paraformaldehyde (10 minutes at room temperature)

  • Permeabilization: 0.1% Triton X-100 (5 minutes)

  • Blocking: 5% BSA or normal serum (1 hour)

• Antibody incubation:

  • Primary antibody: Anti-YOL118C (1:100-1:500 dilution, overnight at 4°C)

  • Secondary antibody: Fluorophore-conjugated (1:500-1:1000, 1 hour at room temperature)

• Co-localization markers:

  • Mitochondria: MitoTracker or anti-COX IV

  • ER: anti-calnexin or anti-PDI

  • Golgi: anti-GM130

  • Nucleus: DAPI or Hoechst

• Controls:

  • Peptide competition control

  • Secondary-only control

  • YOL118C knockdown/knockout sample

As noted in immunophenotyping studies of CD26, epitope masking can occur under certain conditions , so researchers should validate antibody accessibility in their specific experimental setup.

How should researchers approach YOL118C antibody cross-reactivity analysis across species?

Cross-species reactivity assessment is critical for translational research. A methodical approach includes:

• Sequence alignment analysis:

  • Compare YOL118C sequences across target species

  • Identify conserved epitope regions

  • Predict potential cross-reactivity

• Staggered validation protocol:

  Species	Primary Validation	Secondary Validation	Tertiary Validation
  Primary (e.g., yeast)	Western blot	Immunoprecipitation	Mass spectrometry
  Related species	Western blot	Flow cytometry	Immunohistochemistry
  Distant species	ELISA	Dot blot	Functional assay

• Epitope mapping:

  • Peptide array screening

  • Hydrogen-deuterium exchange mass spectrometry

  • X-ray crystallography for antibody-antigen complex

• Functional conservation testing:

  • Assess whether the antibody affects known biological functions of YOL118C across species

  • Evaluate binding kinetics using surface plasmon resonance

What strategies should be employed when analyzing conflicting data from different YOL118C antibody clones?

When faced with discrepancies between antibody clones:

• Systematic clone comparison:

  • Validate each clone against positive and negative controls

  • Map epitopes recognized by each antibody

  • Evaluate potential post-translational modifications that might affect epitope recognition

• Context-dependent validation:

  • Test each antibody under relevant experimental conditions

  • Identify factors that might affect epitope accessibility (fixation methods, buffer conditions)

  • Evaluate whether discrepancies reflect biological reality (e.g., conformational changes, protein interactions)

Drawing from CD26 research experience, where two antibody clones (M-A261 and 5K78) showed dramatically different detection patterns after therapeutic antibody administration, researchers discovered that epitope masking explained the discrepancy . This illustrates how apparent conflicts between antibodies can reveal important biological information.

How can YOL118C antibodies be integrated into oxidative stress response pathway studies?

Given YOL118C's association with oxidative stress tolerance , antibodies against it could be valuable for mechanistic studies:

• Stress-induced expression dynamics:

  • Quantify YOL118C protein levels across different oxidative stressors (H₂O₂, paraquat, menadione)

  • Compare acute vs. chronic expression patterns

  • Correlate with other stress response proteins (e.g., TSA1, TSA2)

• Protein interaction analysis:

  • Use anti-YOL118C for co-immunoprecipitation followed by mass spectrometry

  • Perform proximity ligation assays to identify in situ interactions

  • Establish interaction networks under basal vs. stressed conditions

• Subcellular redistribution:

  • Track YOL118C localization changes during stress response

  • Correlate with organelle stress markers

  • Identify potential regulatory post-translational modifications

• Functional domain analysis:

  • Generate domain-specific antibodies

  • Assess accessibility changes during stress (potentially indicating conformational changes)

  • Map regions critical for stress-induced interactions

This approach draws methodologically from studies examining buffering mechanisms in stress response pathways, where increased expression of specific factors provides enhanced tolerance .

What considerations should guide YOL118C antibody applications in genetic interaction studies?

For genetic interaction studies involving YOL118C:

• Strain validation:

  • Confirm YOL118C expression levels in wild-type vs. mutant strains

  • Verify antibody specificity across genetic backgrounds

  • Establish detection thresholds for quantitative analysis

• Epistasis analysis approach:

  • Create a panel of strains with YOL118C and interacting gene mutations

  • Quantify YOL118C protein levels across genetic backgrounds

  • Correlate protein expression with phenotypic readouts

• Dosage effect studies:

  • Examine protein levels in aneuploid strains with altered YOL118C copy number

  • Assess compensatory changes in interacting proteins

  • Correlate with functional readouts like oxidative stress tolerance

Research on chromosome duplications affecting oxidative stress tolerance genes demonstrates how gene dosage can buffer expression of stress-responsive genes during prolonged stress exposure . Similar approaches could be applied to study YOL118C's role in stress response networks.

What criteria should guide humanization of YOL118C antibodies for potential therapeutic applications?

For researchers considering therapeutic development:

• Humanization approach selection:

  • CDR grafting: Transfer complementarity-determining regions onto human framework

  • Veneering: Surface residue replacement to reduce immunogenicity

  • Phage display: Selection of fully human antibodies

• Critical quality attributes to monitor:

  • Binding affinity (should maintain or improve upon parent antibody)

  • Specificity (cross-reactivity profile)

  • Stability (thermal and colloidal)

  • Effector functions (if desired)

• Functional validation:

  • Compare humanized vs. parent antibody in all relevant assays

  • Assess potential changes in epitope recognition

  • Evaluate pharmacokinetic properties

The development of YS110, a humanized IgG1 monoclonal antibody targeting CD26, demonstrates the importance of maintaining binding characteristics while reducing immunogenicity for clinical applications .

How should researchers design pharmacodynamic monitoring for YOL118C antibody studies?

Comprehensive pharmacodynamic monitoring should include:

• Target engagement metrics:

  • Free vs. bound YOL118C levels

  • Receptor occupancy (if YOL118C functions as a receptor)

  • Downstream signaling markers

• Sample collection timeline:

  Timepoint	Primary Analysis	Secondary Analysis
  Baseline	Target levels	Pathway activity
  24-48h post-dose	Target engagement	Initial response
  1-2 weeks	Sustained effects	Compensatory mechanisms
  Extended follow-up	Duration of effect	Long-term adaptation

• Biomarker panel development:

  • Direct markers: YOL118C protein levels, associated enzymatic activity

  • Indirect markers: Downstream pathway activation, stress response indicators

  • Functional readouts: Cellular phenotype changes

The YS110 antibody trial implemented a comprehensive approach including immunomonitoring of peripheral blood lymphocytes, serum cytokine measurements, and soluble target protein quantification , providing a methodological template.